DOCSLIB.ORG

ONCOGENOMICS Ubiquitin E3 Ligase WWP1 As an Oncogenic Factor in Human Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ONCOGENOMICS Ubiquitin E3 Ligase WWP1 As an Oncogenic Factor in Human Prostate Cancer Oncogene (2007) 26, 2386–2394 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ONCOGENOMICS Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer C Chen1,2, X Sun1, P Guo1, X-Y Dong1, P Sethi1, W Zhou1, Z Zhou2, J Petros1,3,4, HF Frierson Jr5, RL Vessella6, A Atfi7 and J-T Dong1,3,8 1Winship Cancer Institute and Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, USA; 2Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY, USA; 3Department of Urology, Emory University School of Medicine, Atlanta, GA, USA; 4Atlanta VA Medical Center, Decatur, GA, USA; 5Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA; 6Department of Urology, University of Washington, Seattle, WA, USA; 7INSERM U482, Hoˆpital St-Antoine, Paris, France and 8Department of Genetics and Cell Biology, Nankai University College of Life Sciences, Tianjin, China The gene for E3 ubiquitin ligase WWP1 is located at Introduction 8q21, a region frequently amplified in human cancers, including prostate cancer. Recent studies have shown that Prostate cancer is one of the most common solid tumors WWP1 negatively regulates the TGFb tumor suppressor in men. The molecular basis of prostate cancer is not pathway by inactivating its molecular components, well understood, although it has been recognized that including Smad2, Smad4 and TbR1. These findings identifying molecular alterations underlying the deve- suggest an oncogenic role of WWP1 in carcinogenesis, lopment and progression of prostate cancer will be but direct supporting evidence has been lacking. In this necessary for improving its detection and treatment. study, we examined WWP1 for gene dosage, mRNA Copy number gain or loss is a common genetic expression, mutation and functions in a number of human alteration in solid tumors. Many chromosomal regions prostate cancer samples. We found that the WWP1 gene have been identified for such changes in cancer by had copy number gain in 15 of 34 (44%) xenografts and comparative genomic hybridization (CGH) and other cell lines from prostate cancer and 15 of 49 (31%) clinical approaches, yet the underlying target genes remain to be prostate cancer samples. Consistently, WWP1 was over- identified and characterized for most cancers. The q21 expressed in 60% of xenografts and cell lines from band of chromosome 8 (8q21) shows frequent copy prostate cancer. Mutation of WWP1 occurred infre- number gain in prostate cancer, and the gain at 8q21 is quently in prostate cancer. Functionally, WWP1 over- often associated with aggressive behaviors of prostate expression promoted colony formation in the 22Rv1 cancer. For example, in men with clinically localized prostate cancer cell line. In PC-3 prostate cancer cells, prostate cancer, gain of 8q21 is associated with poor WWP1 knockdown significantly suppressed cell prolifera- outcome and metastasis (Nupponen et al., 1998; van tion and enhanced TGFb-mediated growth inhibition. Dekken et al., 2003; Rubin et al., 2004). Therefore, 8q21 These findings suggest that WWP1 is an oncogene that is believed to harbor an important oncogene for prostate undergoes genomic amplification at 8q21 in human cancer. prostate cancer, and WWP1 overexpression is a common Many important molecules involved in cell proli- mechanism involved in the inactivation of TGFb function feration, differentiation and carcinogenesis are tightly in human cancer. controlled by different mechanisms, including ubiquitin Oncogene (2007) 26, 2386–2394. doi:10.1038/sj.onc.1210021; proteasome pathway (UPP)-mediated protein degrada- published online 2 October 2006 tion. Many E3 ubiquitin ligases in the UPP have been implicated in cell cycle control and uncontrolled cell ONCOGENOMICS Keywords: WWP1; amplification; overexpression; prostate proliferation. Some E3 ligases such as MDM2 and cancer; KLF5; TGFb SKP2, which target p53 and CDKN1A/CDKN1B, are considered oncoproteins (Leite et al., 2001; Lu et al., 2002; Drobnjak et al., 2003), while some other E3 ligases are considered tumor suppressors. WWP1 is an E3 ubiquitin ligase that contains four tandem WW domains and a HECT domain. Published studies suggest that WWP1 plays a role in different biological processes Correspondence: Dr JT Dong, Winship Cancer Institute, Emory including regulation of epithelial sodium channels, University School of Medicine, 1365 Clifton Road, Room C4080, viral budding, receptor trafficking and transcription Atlanta, GA 30322, USA. E-mail: [email protected] (Malbert-Colas et al., 2003; Ingham et al., 2004; Received 27 April 2006; revised 26 June 2006; accepted 30 June 2006; Zhang et al., 2004). With regard to a role in published online 2 October 2006 cell proliferation and carcinogenesis, it has been WWP1 in prostate cancer C Chen et al 2387 demonstrated that WWP1 negatively regulates the Results TGFb tumor suppressor pathway by mediating the ubiquitination and degradation of multiple components Frequent copy number gain of the pathway, including Smad2 (Seo et al., 2004), The WWP1 gene is located in the q21 band of Smad4 (Moren et al., 2005), and TGFb receptor 1 chromosome 8 (8q21), which is frequently amplified in (TbR1) proteins (Komuro et al., 2004). WWP1 appears human prostate cancer, including the PC-3 prostate to be regulated by androgen, and is highly expressed cancer cell line (Porkka et al., 2002; Wang et al., 2004). in androgen-independent prostate cancer cells in the To evaluate if WWP1 undergoes genomic amplification LAPC-9 model (Gu et al., 2005). In our recent in prostate cancer, we first examined WWP1’s DNA study, we found that WWP1 also mediates the ubi- copy number in 34 prostate cancer cell lines/xenografts quitination and degradation of the KLF5 transcription by using real-time polymerase chain reaction (PCR) factor, which was identified as a candidate tumor assay, with normal human DNA as a normal control suppressor gene in prostate and breast cancers (Chen and PC-3 prostate cancer cell line as a control with et al., 2002, 2003a, 2005a). Consistent with a previous doubled WWP1 genome. Fifteen of the 34 cases (44%) study showing upregulation of WWP1 in multiple showed an increased copy number by at least one fold carcinoma cell lines (Komuro et al., 2004), we found (Figure 1a). Among the samples examined, LuCaP 23.1, that WWP1 is overexpressed in some prostate and LuCaP 23.12 and LuCaP 23.8 were from different breast cancer cell lines. Furthermore, WWP1 over- metastases of one patient. LuCap35 and LuCaP35V expression leads to excessive degradation of KLF5 in were also from one patient. Cell line 22Rv1 was derived these cancer samples (Chen et al., 2005a, b). These from the CWR22 xenograft. As all these samples were in findings suggest that WWP1 could have an oncogenic the non-amplified group, the actual amplification rate role in prostate cancer. for WWP1 could be higher than described in this study. In this study, we performed genetic and functional Conversely, none of the four un-transformed cell lines analyses to evaluate the role of WWP1 in human (PZ-HPV-7, PWR-1E, RWPE-1 and BPH55T) showed prostate cancer. Both copy number gain and over- a copy number change at WWP1. In agreement with expression were frequently detected in human prostate previous findings, the PC-3 prostate cancer cell line had cancer samples, although mutations were rare. Func- a doubled copy number for WWP1 when compared to tionally, WWP1 overexpression appeared to promote normal samples. Increased copy number at WWP1 was cell proliferation by antagonizing TGFb’s inhibitory also validated in six of the 34 samples by duplex PCR effect on cell proliferation. combined with gel electrophoresis (Figure 1a, inset), Figure 1 Frequent copy number gain at WWP1 in prostate cancer. (a) WWP1 copy numbers in cell lines and xenografts from prostate cancer, as detected by real-time PCR. The KAI1 gene serves as a control for normalizing input DNA. Black bars indicate samples with WWP1 copy number gain. The empty bars indicate non-transformed prostate samples, while gray bars indicate tumor samples without obvious copy number gains. The inset shows WWP1 copy number gain in six prostate cancer samples detected by duplex PCR and gel electrophoresis. (b) Examples of WWP1 copy number gain in clinical prostate cancer specimens detected by duplex PCR assay. Case numbers are shown at the top. N, normal; T, tumor. Oncogene WWP1 in prostate cancer C Chen et al 2388 with normal human DNA and BPH55T untransformed cell line as negative controls. To determine if WWP1 also has copy number gains in clinical prostate cancer samples, we examined 49 cases of prostate cancer and their matched normal cells by performing duplex PCR and gel electrophoresis, which was developed and used to detect gene dosage in our previous studies (Dong et al., 2000; Chen et al., 2003a). As shown in Figure 1b, the ratios between WWP1 signals and control KAI1 signals were significantly greater (>2) than that in the normal DNA in 15 of 49 (31%) tumors examined. It is worth noting that eight of 49 (16%) tumors appeared to have copy number losses at WWP1. No significant association was found between copy number change at WWP1 and age at diagnosis, tumor grade, or tumor stage, which could be due to the smaller sample size. WWP1 expression is frequently upregulated in prostate cancer Copy number gain often causes overexpression for a gene. To test whether WWP1 is overexpressed in prostate cancer, we first examined WWP1 mRNA expression by real time PCR in 30 cell lines and xenografts from prostate cancer. Compared to the average level of WWP1 expression in six non-trans- formed prostate samples, the level of WWP1 expression was increased by at least onefold in 18 of 30 (60%) prostate cancer samples, including the PC-3 prostate Figure 2 Increased expression of WWP1 RNA in prostate cancer.
Load more

Recommended publications
  • Genome-Wide Analysis of HECT E3 Ubiquitin Ligase Gene Family In
    www.nature.com/scientificreports OPEN Genome‑wide analysis of HECT E3 ubiquitin ligase gene family in Solanum lycopersicum Bhaskar Sharma1,2*, Harshita Saxena2 & Harshita Negi2 The E3 ubiquitin ligases have been known to intrigue many researchers to date, due to their heterogenicity and substrate mediation for ubiquitin transfer to the protein. HECT (Homologous to the E6‑AP Carboxyl Terminus) E3 ligases are spatially and temporally regulated for substrate specifcity, E2 ubiquitin‑conjugating enzyme interaction, and chain specifcity during ubiquitylation. However, the role of the HECT E3 ubiquitin ligase in plant development and stress responses was rarely explored. We have conducted an in‑silico genome‑wide analysis to identify and predict the structural and functional aspects of HECT E3 ligase members in tomato. Fourteen members of HECT E3 ligases were identifed and analyzed for the physicochemical parameters, phylogenetic relations, structural organizations, tissue‑specifc gene expression patterns, and protein interaction networks. Our comprehensive analysis revealed the HECT domain conservation throughout the gene family, close evolutionary relationship with diferent plant species, and active involvement of HECT E3 ubiquitin ligases in tomato plant development and stress responses. We speculate an indispensable biological signifcance of the HECT gene family through extensive participation in several plant cellular and molecular pathways. Plant developmental and physiological processes are regulated by the synthesis and degradation of proteins, such that the plant can adapt to the environmental fuctuations while maintaining cellular homeostasis 1. Post- translational modifcations have a major role in protein degradation which limits the protein load in the cells through eradication of unwanted or abnormal proteins, and amino acids are recycled under strict and selec- tive regulation2,3.
    [Show full text]
  • Pathway-Based Network Modeling Finds Hidden Genes in Shrna Screen for Regulators of Acute Cite This: Integr
    Integrative Biology PAPER Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute Cite this: Integr. Biol., 2016, 8,761 lymphoblastic leukemia† Jennifer L. Wilson,a Simona Dalin,b Sara Gosline,a Michael Hemann,b Downloaded from https://academic.oup.com/ib/article/8/7/761/5115211 by guest on 01 October 2021 Ernest Fraenkel*ab and Douglas A. Lauffenburger*a Data integration stands to improve interpretation of RNAi screens which, as a result of off-target effects, typically yield numerous gene hits of which only a few validate. These off-target effects can result from seed matches to unintended gene targets (reagent-based) or cellular pathways, which can compensate for gene perturbations (biology-based). We focus on the biology-based effects and use network modeling tools to discover pathways de novo around RNAi hits. By looking at hits in a functional context, we can uncover novel biology not identified from any individual ‘omics measurement. We leverage multiple ‘omic measurements using the Simultaneous Analysis of Multiple Networks (SAMNet) computational framework to model a genome scale shRNA screen investigating Acute Lymphoblastic Leukemia (ALL) progression in vivo. Our network model is enriched for cellular processes associated with hematopoietic differentiation and homeostasis even though none of the individual ‘omic sets showed this enrichment. The model identifies genes associated with the TGF-beta pathway and predicts a role in ALL progression for many genes without this functional annotation. We further experimentally validate the hidden genes – Wwp1, a ubiquitin ligase, and Hgs, a multi-vesicular body associated protein – for their role in ALL progression.
    [Show full text]
  • The Teleost Agouti-Related Protein 2 Gene Is an Ohnolog Gone Missing
    paralogies with the region on Hsa8 (Fig. 1D). According to our LETTER model (Fig. 1E), an ancestral Asip/Agrp precursor gene was duplicated two times during the two rounds of vertebrate ge- The teleost agouti-related protein 2 nome duplication (R1 and R2). After R2, Asip and Agrp were gene is an ohnolog gone missing retained in all bony vertebrates, but a third ohnolog (4) went missing in the tetrapod lineage. This gene was retained, however, from the tetrapod genome in the rayfin fish lineage, giving rise to agrp2 and asip2 after the TSGD. A central question in evolutionary genomics is how morpholog- Our results support a revision of agouti family nomenclature ical differences between taxa arise from differences in gene (Fig. 1E). Importantly, our model suggests that the genetic repertoire. Answers require rigorous orthology assignments. basis of teleost background adaptation may not root in the agouti Recent work (1) illuminated the mechanism of background ad- family expansion during the TSGD but to R2, far deeper in aptation in teleost fishes by investigating the function of agouti- vertebrate evolution (Fig. 1E). It is unlikely that zebrafish agrp2 related protein 2 (agrp2), a gene so far found only in teleosts. (new name: asip2b) newly evolved its single pineal-specific Agouti family proteins antagonize melanocortin receptors, function after the TSGD (as suggested by ref. 1), because asip2 function in energy homeostasis, and regulate pigmentation. (asip2a) is absent in zebrafish but present in other teleosts. The authors (1) proposed a
    [Show full text]
  • Meeting Report of the 26Th International Mammalian Genome Conference
    Mamm Genome (2013) 24:179–189 DOI 10.1007/s00335-013-9455-1 Meeting report of the 26th International Mammalian Genome Conference Melissa A. Musser • Steven C. Munger • Teresa M. Gunn Received: 26 February 2013 / Accepted: 23 April 2013 / Published online: 15 May 2013 Ó Springer Science+Business Media New York 2013 Introduction enable us to expand the scope of our research questions and the mammalian systems we use to answer them. At the A diverse group of geneticists, clinicians, and bioinfor- same time, the Verne Chapman Lecture provided valuable maticians converged on sunny St. Pete Beach, Florida, historical perspective on the role of mammalian models October 21–24, 2012, for the 26th International Mamma- over the last half-century, and predicted the future oppor- lian Genome Conference (IMGC). Organized by Michelle tunities and challenges facing geneticists in the next 50 Southard-Smith (Vanderbilt University) and Teresa Gunn years. Abstracts from the meeting are available at (McLaughlin Research Institute) with help from the IMGS www.imgs.org, and online databases and resources pre- Secretariat, the conference attracted 148 participants from sented at the meeting are listed in Table 1. 14 countries. Investigators, postdoctoral fellows, and graduate students returned to the site of the popular 11th IMGC (1997) to share exciting advances in mammalian The power of genetics genetics and genomics research, findings that underscored the continued and future importance of mammalian genetic The power of High Throughput Sequencing (HTS) was
    [Show full text]
  • Identification of Significant Pathways in Gastric Cancer Based on Protein-Protein Interaction Networks and Cluster Analysis
    Genetics and Molecular Biology, 35, 3, 701-708 (2012) Copyright © 2012, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Research Article Identification of significant pathways in gastric cancer based on protein-protein interaction networks and cluster analysis Kongwang Hu1 and Feihu Chen2 1Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, P.R. China. 2School of Pharmacology, Anhui Medical University, Anhui, P.R. China. Abstract Gastric cancer is one of the most common and lethal cancers worldwide. However, despite its clinical importance, the regulatory mechanisms involved in the aggressiveness of this cancer are still poorly understood. A better under- standing of the biology, genetics and molecular mechanisms of gastric cancer would be useful in developing novel targeted approaches for treating this disease. In this study we used protein-protein interaction networks and cluster analysis to comprehensively investigate the cellular pathways involved in gastric cancer. A primary immunodefi- ciency pathway, focal adhesion, ECM-receptor interactions and the metabolism of xenobiotics by cytochrome P450 were identified as four important pathways associated with the progression of gastric cancer. The genes in these pathways, e.g., ZAP70, IGLL1, CD79A, COL6A3, COL3A1, COL1A1, CYP2C18 and CYP2C9, may be considered as potential therapeutic targets for gastric cancer. Key words: graph clustering, pathway crosstalk, protein-protein interaction network. Received: March 12, 2012; Accepted: May 4, 2012. Introduction mal persons (Offerhaus et al., 1992). b-catenin is fre- Gastric cancer is one of the most common malignan- quently mutated in gastric cancer (Clements et al., 2002). In cies worldwide (Lin et al., 2007b).
    [Show full text]
  • Molecular Evolution, Neurodevelopmental Roles and Clinical Significance of HECT-Type UBE3 E3 Ubiquitin Ligases
    cells Review Molecular Evolution, Neurodevelopmental Roles and Clinical Significance of HECT-Type UBE3 E3 Ubiquitin Ligases Mateusz C. Ambrozkiewicz 1,* , Katherine J. Cuthill 1, Dermot Harnett 2, Hiroshi Kawabe 3 and Victor Tarabykin 1,4,* 1 Institute of Cell Biology and Neurobiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany; [email protected] 2 The Integrative Research Institute for the Life Sciences, Institute of Biology, Humboldt-Universität zu Berlin, 10115 Berlin, Germany; [email protected] 3 Department of Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan; [email protected] 4 Institute of Neuroscience, Lobachevsky University of Nizhny Novgorod, pr. Gagarina 24, 603950 Nizhny Novgorod, Russia * Correspondence: [email protected] (M.C.A.); [email protected] (V.T.) Received: 14 October 2020; Accepted: 7 November 2020; Published: 10 November 2020 Abstract: Protein ubiquitination belongs to the best characterized pathways of protein degradation in the cell; however, our current knowledge on its physiological consequences is just the tip of an iceberg. The divergence of enzymatic executors of ubiquitination led to some 600–700 E3 ubiquitin ligases embedded in the human genome. Notably, mutations in around 13% of these genes are causative of severe neurological diseases. Despite this, molecular and cellular context of ubiquitination remains poorly characterized, especially in the developing brain. In this review article, we summarize recent findings on brain-expressed HECT-type E3 UBE3 ligases and their murine orthologues, comprising Angelman syndrome UBE3A, Kaufman oculocerebrofacial syndrome UBE3B and autism spectrum disorder-associated UBE3C.
    [Show full text]
  • 1 Supplementary Material Figure S1. Volcano Plot of Differentially
    Supplementary material Figure S1. Volcano Plot of differentially expressed genes between preterm infants fed own mother’s milk (OMM) or pasteurized donated human milk (DHM). Table S1. The 10 most representative biological processes filtered for enrichment p- value in preterm infants. Biological Processes p-value Quantity of DEG* Transcription, DNA-templated 3.62x10-24 189 Regulation of transcription, DNA-templated 5.34x10-22 188 Transport 3.75x10-17 140 Cell cycle 1.03x10-13 65 Gene expression 3.38x10-10 60 Multicellular organismal development 6.97x10-10 86 1 Protein transport 1.73x10-09 56 Cell division 2.75x10-09 39 Blood coagulation 3.38x10-09 46 DNA repair 8.34x10-09 39 Table S2. Differential genes in transcriptomic analysis of exfoliated epithelial intestinal cells between preterm infants fed own mother’s milk (OMM) and pasteurized donated human milk (DHM). Gene name Gene Symbol p-value Fold-Change (OMM vs. DHM) (OMM vs. DHM) Lactalbumin, alpha LALBA 0.0024 2.92 Casein kappa CSN3 0.0024 2.59 Casein beta CSN2 0.0093 2.13 Cytochrome c oxidase subunit I COX1 0.0263 2.07 Casein alpha s1 CSN1S1 0.0084 1.71 Espin ESPN 0.0008 1.58 MTND2 ND2 0.0138 1.57 Small ubiquitin-like modifier 3 SUMO3 0.0037 1.54 Eukaryotic translation elongation EEF1A1 0.0365 1.53 factor 1 alpha 1 Ribosomal protein L10 RPL10 0.0195 1.52 Keratin associated protein 2-4 KRTAP2-4 0.0019 1.46 Serine peptidase inhibitor, Kunitz SPINT1 0.0007 1.44 type 1 Zinc finger family member 788 ZNF788 0.0000 1.43 Mitochondrial ribosomal protein MRPL38 0.0020 1.41 L38 Diacylglycerol
    [Show full text]
  • S41467-019-11224-7.Pdf
    ARTICLE https://doi.org/10.1038/s41467-019-11224-7 OPEN A multi-lock inhibitory mechanism for fine-tuning enzyme activities of the HECT family E3 ligases Zhen Wang1,3, Ziheng Liu1,3, Xing Chen1, Jingyu Li1, Weiyi Yao1, Shijing Huang1, Aihong Gu1, Qun-Ying Lei 1,2, Ying Mao1 & Wenyu Wen 1 HECT E3 ligases control the degradation and functioning of numerous oncogenic/tumor- suppressive factors and signaling proteins, and their activities must be tightly regulated to 1234567890():,; prevent cancers and other diseases. Here we show that the Nedd4 family HECT E3 WWP1 adopts an autoinhibited state, in which its multiple WW domains sequester HECT using a multi-lock mechanism. Removing WW2 or WW34 led to a partial activation of WWP1. The structure of fully inhibited WWP1 reveals that many WWP1 mutations identified in cancer patients result in a partially active state with increased E3 ligase activity, and the WWP1 mutants likely promote cell migration by enhancement of ΔNp63α degradation. We further demonstrate that WWP2 and Itch utilize a highly similar multi-lock autoinhibition mechanism as that utilized by WWP1, whereas Nedd4/4 L and Smurf2 utilize a slightly variant version. Overall, these results reveal versatile autoinhibitory mechanisms that fine-tune the ligase activities of the HECT family enzymes. 1 Department of Neurosurgery, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China. 2 Fudan University Shanghai Cancer Center and Cancer Metabolism Laboratory, Fudan University, Shanghai 200032, China.
    [Show full text]
  • Supplemental Figure 1. Details Parallel Those Outlined in Figure 5 Legend
    Supplemental Figure 1. Details parallel those outlined in Figure 5 legend. Longitudinal Progressor Series Longitudinal AA+ HRS Series Longitudinal AA- HRS Series Longitudinal AA- LRS Series A B E F D A B C E F G H I J A B C D E F G H I J K L B C D E F G 21.67 9.02 19.33 6.9 17.38 Age at onset: 6.28 7.30 8.27 9.53 3.05 4.05 6.01 7.16 7.07 8.08 9.08 7.31 9.30 5.46 6.69 7.99 2.58 7.07 7.94 9.97 2.13 5.99 7.13 8.01 9.10 4.53 9.95 2.16 3.07 4.08 6.11 2.20 4.22 5.13 6.49 7.24 8.38 9.76 7.41 8.43 9.39 5.51 8.81 2.86 4.97 6.71 9.24 R O T 1 D 5.35 6.37 7.35 8.35 9.15 9.84 2.61 3.22 4.37 5.43 7.84 9.59 Age: 2.09 8.86 9.99 3.81 5.83 6.75 8.11 8.33 9.42 10.08 Time to onset: 7.31 10.37 15.31 16.50 17.65 18.85 11.15 10.56 11.65 11.07 10.16 14.34 10.54 12.53 13.55 14.55 15.54 16.54 6.48 5.45 4.29 3.93 3.44 2.42 1.36 10.23 11.59 12.35 6.95 4.95 3.95 2.96 2.47 1.92 1.40 0.37 2.90 10.32 11.32 12.31 13.31 1.50 2.71 2.25 1.47 0.97 18.65 14.80 16.36 17.36 18.35 5.32 3.32 2.44 1.47 0.33 14.67 15.66 16.64 17.67 11.37 12.58 13.57 14.63 15.67 16.58 12.02 13.84 15.14 16.02 16.91 10.81 11.83 12.85 14.03 15.09 16.02 17.10 19.52 15.78 16.45 17.62 18.73 19.71 10.97 11.49 12.02 12.66 10.45 11.26 12.33 12.12 12.39 14.44 13.36 14.03 14.65 14.25 11.29 12.37 13.29 14.27 LRS u H C HRS - - - - - - - - - - - - - - +0.17 - +0.15 +1.09 +0.10 - - - - - - +0.84 - - - - - +0.27 +0.57 LRS n=575 138↑; 437↓ ROT1D n=128 HRS n=156 HC n=647 532↑; 115↓ AA Status: 0 1 3 3 3 4 4 1 2 3 2 4 3 3 3 3 3 3 1 4 3 4 4 4 4 0 0 0 3 3 3 3 4 4 4 4 4 3 3 2 3 2 3 2 2 2 1 1 1 2 2 2 2 0 2 1 1 1 1 1 0
    [Show full text]
  • The Emerging Role of WWP1 in Cancer Development and Progression ✉ ✉ Xiaoli Hu1, Jiangtao Yu1, Zixia Lin2,3, Renqian Feng1, Zhi-Wei Wang 4 and Gang Chen2,3
    www.nature.com/cddiscovery REVIEW ARTICLE OPEN The emerging role of WWP1 in cancer development and progression ✉ ✉ Xiaoli Hu1, Jiangtao Yu1, Zixia Lin2,3, Renqian Feng1, Zhi-wei Wang 4 and Gang Chen2,3 © The Author(s) 2021 Emerging evidence demonstrates that WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) participates into carcinogenesis and tumor progression. In this review article, we will describe the association between dysregulated WWP1 expression and clinical features of cancer patients. Moreover, we summarize the both oncogenic and tumor suppressive functions of WWP1 in a variety of human cancers. Furthermore, we briefly describe the downstream substrates of WWP1 and its upstream factors to regulate the expression of WWP1. Notably, targeting WWP1 by its inhibitors or natural compounds is potentially useful for treating human malignancies. Finally, we provide the perspectives regarding WWP1 in cancer development and therapies. We hope this review can stimulate the research to improve our understanding of WWP1-mediated tumorigenesis and accelerate the discovery of novel therapeutic strategies via targeting WWP1 expression in cancers. Cell Death Discovery (2021) 7:163 ; https://doi.org/10.1038/s41420-021-00532-x FACTS activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3) [3]. Two E1 enzymes, 38 E2 enzymes, and ● more than 600 E3 enzymes are reported in humans. Based on WWP1 mainly targets its substrates for ubiquitination and their structures, E3 ligases are mainly divided into three groups: degradation. – ● RING-type E3s, HECT-type E3s, and RBR E3s [4 7]. HECT-type E3 Targeting WWP1 could be useful for improving therapeutic ligases are classified into three families according to diverse outcome of cancer patients.
    [Show full text]
  • Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity Without Compromising Cisplatin Anticancer Properties
    BASIC RESEARCH www.jasn.org Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties † ‡ Ramindhu Galgamuwa,* Kristine Hardy, Jane E. Dahlstrom, Anneke C. Blackburn,* Elize Wium,* Melissa Rooke,* Jean Y. Cappello,* Padmaja Tummala,* Hardip R. Patel,§ | Aaron Chuah, Luyang Tian,¶ Linda McMorrow,** Philip G. Board,* and Angelo Theodoratos* *Departments of Cancer Biology and Therapeutics and §Genome Sciences, and |Genome Discovery Unit, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia; †Faculty of Education, Science, Technology and Mathematics, University of Canberra, Australian Capital Territory, Australia; ‡ACT Pathology and ANU Medical School, The Canberra Hospital, Australian Capital Territory, Australia; ¶Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; and **Archaeogeochemistry and Marine Biogeochemistry Groups, Research School of Earth Sciences, Australian National University, Australian Capital Territory, Australia ABSTRACT Cisplatin is an effective anticancer drug; however, cisplatin use often leads to nephrotoxicity, which limits its clinical effectiveness. In this study, we determined the effect of dichloroacetate, a novel anticancer agent, in a mouse model of cisplatin-induced AKI. Pretreatment with dichloroacetate significantly attenuated the cisplatin-induced increase in BUN and serum creatinine levels, renal tubular apoptosis, and oxidative stress. Additionally, pretreatment with dichloroacetate
    [Show full text]
  • HECT-Type Ubiquitin Ligases in Nerve Cell Development
    HECT-type Ubiquitin Ligases in Nerve Cell Development Dissertation in partial fulfillment of the requirements for the award of the degree ”Doctor rerum naturalium” of the Georg August University Göttingen, Faculty of Biology within the doctoral program Neurosciences of the Georg August University School of Science submitted by Mateusz Cyryl Ambrożkiewicz Born in Puławy, Poland Göttingen, 2015 Thesis Committee Prof. Nils Brose, Department of Molecular Neurobiology, Max Planck Institute for Experimental Medicine, Göttingen Dr. Judith Stegmüller, Cellular and Molecular Neurobiology, Max Planck Institute for Experimental Medicine, Göttingen Prof. Ahmed Mansouri, Research Group Molecular Cell Differentiation, Max Planck Institute for Biophysical Chemistry, Göttingen Members of the Examination Board Referee: Prof. Nils Brose, Department of Molecular Neurobiology, Max Planck Institute for Experimental Medicine, Göttingen 2nd Referee: Dr. Judith Stegmüller, Cellular and Molecular Neurobiology, Max Planck Institute for Experimental Medicine, Göttingen 3rd referee: Prof. Ahmed Mansouri, Research Group Molecular Cell Differentiation, Max Planck Institute for Biophysical Chemistry, Göttingen Further members of the Examination Board Camin Dean, Ph. D., Trans-Synaptic Signaling, European Neuroscience Institute, Göttingen Prof. Thomas Dresbach, Department of Anatomy and Embryology, University Medical Center Göttingen Prof. Tobias Moser, Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen Date of oral examination: 19th November 2015 II DECLARATION Herewith I declare, that I prepared the Doctoral Thesis "HECT-type Ubiquitin Ligases in the Nerve Cell Development" on my own, and with no other sources and aids than quoted. This work was partly supported by the Ph.D. program "Neurosciences" – International Max Planck Research School at the Georg August University Göttingen. Mateusz Ambrożkiewicz Göttingen, 21st September, 2015 III Niczego w życiu nie należy sie bać, należy to tylko zrozumieć.
    [Show full text]